Viral Inhibition in Children for Treatment of RSV (VICTOR)
A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection
Sponsor: Ark Biosciences Pty Ltd.
Listed as NCT02654171, this PHASE2 trial focuses on RESPIRATORY SYNCYTIAL VIRUS INFECTIONS and remains completed. Sponsored by Ark Biosciences Pty Ltd., it has been updated 12 times since 2016, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Feb 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ark Biosciences Pty Ltd.
- Shanghai Ark Biopharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .